Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Lorlatinib + Saracatinib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Lorlatinib||Lorbrena||PF-06463922||ALK Inhibitor 22 ROS1 Inhibitor 14||Lorbrena (lorlatinib) is a small molecule inhibitor of Alk and Ros1 fusion proteins, which may result in suppression of Alk and Ros1-mediated signaling thereby inhibiting cell growth and causing tumor regression (PMID: 26144315). Lorbrena (lorlatinib) is FDA approved for use in patients with ALK-positive non-small cell lung cancer (FDA.gov).|
|Saracatinib||AZD0530||BCR-ABL Inhibitor 24 SRC Inhibitor 28||Saracatinib (AZD0530) is a multi-kinase inhibitor with activity against ABL and SRC, which may block proliferation, metastasis, and survival in cancer cells (PMID: 19393585).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|EML4 - ALK ALK C1156Y ALK G1269A||lung adenocarcinoma||sensitive||Lorlatinib + Saracatinib||Preclinical - Patient cell culture||Actionable||In a preclinical study, Saracatinib (AZD0530) and Lorbrena (lorlatinib) synergistically inhibited viability of cells derived from the tumor from a patient with lung adenocarcinoma harboring EML4-ALK and acquired ALK C1156Y and G1269A compound mutation in culture (PMID: 31585938).||31585938|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|